Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells

mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation

(2021) Yilei Zhang et al.   Nature Communications

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

(2020) Sanne C. F. A. Huijberts et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo

(2020) Shunnan Yao et al.   CANCER LETTERS

Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers

(2020) Bowen Li et al.   BIOMEDICINE & PHARMACOTHERAPY

Neuroprotective Effects of the Anti-cancer Drug Lapatinib Against Epileptic Seizures via Suppressing Glutathione Peroxidase 4-Dependent Ferroptosis

(2020) Ji-Ning Jia et al.   Frontiers in Pharmacology

Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib

(2020) Xiang Song et al.   Frontiers in Oncology

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies

(2020) Alessandro Russo et al.   Translational Lung Cancer Research

Sigma‐1 receptor protects against ferroptosis in hepatocellular carcinoma cells

(2019) Tao Bai et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin

(2019) Xuefei Zhang et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Lysosomal Destabilizing Drug Siramesine and the Dual Tyrosine Kinase Inhibitor Lapatinib Induce a Synergistic Ferroptosis through Reduced Heme Oxygenase-1 (HO-1) Levels

(2019) Gloria E. Villalpando-Rodriguez et al.   Oxidative Medicine and Cellular Longevity

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

(2019) Ana C.Z. Gelatti et al.   LUNG CANCER

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

(2018) J Remon et al.   ANNALS OF ONCOLOGY

Role of GPX4 in ferroptosis and its pharmacological implication

(2018) Tobias M. Seibt et al.   FREE RADICAL BIOLOGY AND MEDICINE

Anti-tumor effects of Atractylenolide I on bladder cancer cells

(2016) Rui Yu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Translational Regulation of GPx-1 and GPx-4 by the mTOR Pathway

(2014) Emily N. Reinke et al.   PLoS One

Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance

(2012) Sylvia S. Gayle et al.   Anti-Cancer Agents in Medicinal Chemistry

New driver mutations in non-small-cell lung cancer

(2011) William Pao et al.   LANCET ONCOLOGY